WXIBF:OTCMKTS
WuXi Biologics (Cayman) Inc
$6.36
0.00%
(0.00) 1D
$6.95
arrow_upward
+9.28% (+0.59)todayPre-market
Closed: Oct 16, 3:21:56 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WXIBF...
Mkt. cap
206.04B
Avg. vol.
8.88K
Volume
427.00
52-wk high
$7.49
52-wk low
$3.90
Beta
0.29
Shares outstanding
4.12B
No. of employees
15K
Mkt. cap
206.04B
Avg. vol.
8.88K
Volume
427.00
52-wk high
$7.49
52-wk low
$3.90
Beta
0.29
Shares outstanding
4.12B
No. of employees
15K
News stories
From web sources and news partners
FOREX.com
·
7 minutes ago
USD/JPY and Nasdaq Price Outlook: Key Levels to Watch
FXStreet
·
1 hour ago
Not 1987: Dip buyers return as black Monday anniversary passes quietly
TradingView
·
1 hour ago
Tom Lee Predicts S&P 500 At 8,400 By Year-End, Says Midterm Elections Could Trigger ‘Risk-On’ Rally in Tech Stocks and Crypto: ‘We Are in an Unprecedented Time’
Investing.com
·
2 hours ago
Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish By Investing.com
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc